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This study was initiated to investigate the eﬀ ect of PLGA concentration, PVA concentration, internal to 
external phase ratio (IEPR), PEG molecular weight and concentration on mean particle size, zeta potential, 
polydispersity 
index (PDI), percentage drug entrapment and in vitro release proﬁ le. Using PLGA (50:50) as the carrier, 
insulin 
nanoparticles (NP) were prepared using double emulsion solvent evaporation technique. The particle size was 
analysed by dynamic light scattering (DLS) and the geometrical shape was examined using scanning electron 
microscopy (SEM). Mean particle size was highly dependent on the combined eﬀ ect of PLGA and PVA 
con- 
centrations. Drug entrapment would be greatly controlled by PLGA concentration and internal to external phase 
ratio. Addition of PEG could modulate in vitro release behavior of insulin with initial burst at the ﬁ rst 12 h 
and 
sustain the drug release for 6 days. Insulin integrity was assessed in vitro using MALDI-TOF mass spectroscopy. 
The optimised NP formulation, had particle size of 202.60 nm and percent entrapment eﬃciency (EE) equal to 
67.72%, was tested in vivo to examine its hypoglycemic eﬀ ect after subcutaneous injection. Insulin NP had 
a signiﬁ cant hypoglycemic eﬀ ect comparing to free insulin (p  < 0.01) and insulin zinc suspension (p  < 
0.05). 
 
 
 
1. Introduction 
 
Insulin is a peptide hormone with multiple physiological roles. 
Basically, it regulates blood glucose level and has an additional bene- 
ﬁ cial role in wound healing. Many pathological changes would occur 
if 
insulin level deviated from its normal range [1]. Diabetes is a metabolic 
disease categorised into two types; Type I, an autoimmune pathologic 
process occurs in the pancreatic islets which aﬀ ects negatively on 
in- 
sulin secretion. Type II, the cause is a combination of resistance to in- 
sulin action and a suboptimum compensatory insulin secretory response 
[2]. 
Recently, several drug delivery systems have been developed to 
formulate human insulin in biocompatible nanocarriers such as nano- 
particles, liposomes, dendrimers and other micellar systems to over- 
come its premature degradation by encapsulation within polymeric 
matrix [3]. Special focus is paid on nanoparticles for the delivery of 
insulin via using several natural and synthetic polymers to manufacture 
polymeric nanoparticles. Generally, polymeric materials could help in 
alteration  of  physicochemical  characteristics  (hydrophobicity,  zeta 
potential) of the therapeutic agents, drug release properties (delayed, 
prolonged, triggered) and biological action (bio-adhesion, improved 
cellular uptake) of the NP, also, it increases macromolecules (peptides, 
protein) stability and enhances the solubility of hydrophobic drugs [4]. 
Poly (lactic-co-glycolic acid) (PLGA) has been widely used in na- 
notechnology applications because it is biocompatible, biodegradable, 
commercially available and commonly used in pharmaceutical for- 
mulations approved by the FDA. Poly (ethylene glycol) (PEG) might be 
added as a co-block polymer with PLGA or physically mixed during NP 
preparation. PEG could enhance drug encapsulation and modulate drug 
release proﬁ le to get an initial burst with better sustained eﬀ ect. 
Several 
encapsulation techniques have been used to encapsulate the bioactive 
drugs that can be divided into; chemically polymerisation process 
(emulsion, mini-emulsion and interfacial) and physically incorporation 
method (spray drying, multiple emulsion and solvent diﬀ usion). 
The 
optimum selection of the method would result in a proper particulate 
size and adequate drug encapsulation [3]. 
Double emulsion solvent evaporation technique (w/o/w) plays an 
important  role  in  encapsulating  hydrophilic  drugs  [5].  The  water- 
 
 
  
 
soluble molecules were solubilised in the inner w1 phase then the oily 
organic phase was added using a shear force resulting from homo- 
genisation, and in some circumstances sonication might be used to 
protect highly sensitive peptide from the damage of its dimensional 
structure. The external aqueous medium containing a stabiliser was 
added using the same shear force to form the second emulsion (w/o/w). 
This method exhibits sustained drug release, minimum toxic eﬀ ects 
and 
high encapsulation eﬃciency of the active agent. For this reason, pro- 
teins have been extensively encapsulated by w/o/w emulsion system. 
The physicochemical properties including the stability, globular size, 
surface charge and release properties of double emulsions can be highly 
controlled by several processing parameters (polymer concentration, 
surfactant concentration, ratio between internal and external aqueous 
medium and PEG concentration) that will be discussed in this study. 
Prolonged control of hyperglycemia over several days is a beneﬁ
cial 
gain could be obtained from polymeric insulin NP after subcutaneous 
administration. Most of the marketed products can control the glucose 
level  for  maximally  24  h,  frequent  administration  is  a  signiﬁ
cant 
drawback that should be overcome for patient convenience. The opti- 
mised insulin NP, selected for in vivo study, can maintain the glucose 
level within normal range via single weekly injection with signiﬁ
cant 
di ﬀ erence compared to marketed insulin zinc 
suspension. 
 
2. Materials and methods 
 
2.1. Materials 
 
Insulin, recombinant human, dry powder and poly (D,L-lactide-co- 
glycolide, acid terminated, lactide:glycolide 50:50, MW 24,000–
38,000) were purchased from Sigma Aldrich, UK. Hydrochloric 
acid (HCl), acetic acid and triﬂ uroacetic acid (TFA) solutions 
were 
purchased   from   Fluka,   Sigma   Aldrich,   UK.   Poly   (vinyl   alcohol) 
(MW = 31,000–50,000, 87–89% hydrolysed), poly (ethylene glycol) 
(PEG) ﬂ akes (MW 200, 2000 and 5000 Da), sucrose powder and 
po- 
tassium chloride (KCl) were all purchased from Sigma Aldrich, UK. 
Sodium acetate, 2-(N-cyclohexylamino) ethanesulfonic acid (CHES) and 
triethylamine were all also, purchased from Sigma Aldrich, UK. A bi- 
cinchoninic acid Protein Assay Kit (BCA) was purchased from Thermo 
Fisher  Scienti ﬁ c,  Pierce  Biotechnology  Inc.,  USA.  
Dichloromethane 
(DCM), tri ﬂ uoracetic acid (TFA), acetonitrile (MeCN) and 
methanol 
were of HPLC grade. All other reagents and solvents were of appro- 
priate laboratory standard and used without further puriﬁ cation. 
 
2.2. PLGA NP preparation 
 
Insulin-loaded NP were prepared using a double-emulsion, solvent 
evaporation technique, adapted with minor modiﬁ cations from the 
method described by Feczkó T et al., [6]. Brieﬂ y, X ml of an 
internal 
aqueous insulin solution (5 mg, dissolved in a mixture of 0.1 M HCL and 
PVA 2.5% w/v, pH ≈ 1–2) was added drop-wise to an organic phase 
(4 ml DCM) containing Y mg of PLGA. This organic phase contained 
variations (Z) of PEG content, both in concentration and molecular 
weight. The primary emulsion (w1/o) was homogenised in an ice bath 
for 2 min at 1000 rpm using a low speed homogeniser (Ultra-Turrax® 
T10 Basic Disperser, IKA® Works, VWR®International, UK) before drop- 
wise addition to 50 ml of an external aqueous phase containing Q% w/v 
PVA [7] as de ﬁ ned by the formula codes in Table 1. The 
secondary 
emulsion (w1/o/w2) was stirred continuously for 6 min at 10,000 rpm 
using a high speed homogeniser (model L5M-A Silverson Ltd., UK). 
DCM was evaporated using magnetic stirring for 6–8 h. NP were col- 
lected by centrifugation (3-30k, Sigma Laboratory Centrifuge Hen- 
derson Biomedical Ltd., Germany) at 11,000 × g for 30 min at 4 °C and 
washed with 2% w/v sucrose solution [8]. The pellet was frozen at 
−20 °C for 4–6 h and then lyophilised (4.5 Plus, Labconco Ltd., USA) 
for 48 h. NP were stored in a desiccator at room temperature for in vitro 
characterisation. 
  
 
Table 1 
Formulae identiﬁ cation and composition of insulin-PLGA NP. 
 
Formula code PLGA 
concentration 
(%w/v) 
PVA 
concentration in 
aqueous external 
phase (%w/v) 
Internal - 
external 
phase 
volume 
PEG content 
in primary 
emulsion 
Mw (% w/w) 
   ratio  
   (IEPR)  
M1 2.50 1.25 0.01 – 
M2 2.50 1.25 0.15 – 
M3 2.50 1.25 0.02 – 
M4 2.50 2.50 0.01 – 
M5 2.50 2.50 0.15 – 
M6 2.50 2.50 0.02 – 
M7 2.50 5.00 0.01 – 
M8 2.50 5.00 0.15 – 
M9 2.50 5.00 0.02 – 
M10 5.00 1.25 0.01 – 
M11 5.00 1.25 0.15 – 
M12 5.00 1.25 0.02 – 
M13 5.00 2.50 0.01 – 
M14 5.00 2.50 0.15 – 
M15 5.00 2.50 0.02 – 
M16 5.00 5.00 0.01 – 
M17 5.00 5.00 0.15 – 
M18 5.00 5.00 0.02 – 
M19 7.50 1.25 0.01 – 
M20 7.50 1.25 0.15 – 
M21 7.50 1.25 0.02 – 
M22 7.50 2.50 0.01 – 
M23 7.50 2.50 0.15 – 
M24 7.50 2.50 0.02 – 
M25 7.50 5.00 0.01 – 
M26 7.50 5.00 0.15 – 
M27 7.50 5.00 0.02 – 
F1 2.50 1.25 0.002 – 
F2 2.50 1.25 0.002 200Da (5%) 
F3 2.50 1.25 0.002 200Da 
    (10%) 
F4 2.50 1.25 0.002 2 kDa (5%) 
F5 2.50 1.25 0.002 2 kDa (10%) 
F6 2.50 1.25 0.002 5 kDa (5%) 
F7 2.50 1.25 0.002 5 kDa (10%) 
 
 
2.3. Particle size and zeta potential measurements 
 
An appropriate amount of lyophilised NP were dispersed in 
distilled water or 1.0 Mm KCL solution and then stirred for 3 min 
using the vortex. Particulate size (diameter, nm) and polydispersity 
index (PDI) were determined by dynamic light scattering (DLS) 
(ZetaSizer Nano series, Malvern Instruments, Worcestershire, UK). 
Surface charge (zeta potential, mV) was determined by measuring 
electrophoretic mobility. Measurements were performed in triplicate 
at 25 °C. 
 
2.4. Morphological  characterisation 
 
Lyophilised NP (intact or cracked after exposure to release 
media) and free insulin were coated with a mixture of gold and 
palladium under vacuum for 3 min and examined for morphology 
using scanning electron microscopy at 20 kV (Zeiss, Oberkochen, 
Germany). 
 
2.5. Human insulin analysis 
 
2.5.1. High pressure liquid chromatography (HPLC) 
Reversed phase HPLC (Shimadzu Corporation, Kyoto, Japan) 
method was used to analyse human insulin. A Luna® C18 column (5 
μm, 150 × 4.6 mm, Phenomenex, CA, USA) was utilised as a 
stationary phase. The mobile phase composed from a binary mixture 
of 0.1% TFA in water (solution A) and 0.1% TFA in MeCN 
(solution B) [9] was gradient eluted by increasing solution B 
concentration from 10% to 
35% over a 15-min period at λ max  = 210 nm with a ﬂ ow rate of 
  
 
 
 
Fig. 1. Representative  graphs  showing  particle 
size and PDI measurements using Malvern DlS 
v.6.20  software.  Reported  graph  showed  good 
quality (red arrows) of insulin NP prepared with 
(A) PLGA 2.5% w/w, (B) PLGA 5% w/w. (For 
interpretation of the references to colour in this 
ﬁ gure legend, the reader is referred to the web 
version of this article.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.1 ml min−1. Analysis was conducted at ambient temperature and 
peak area released at predetermined retention time was used to quan- 
tify the analyte. 
 
 
2.5.2. Capillary electrophoresis (CE) 
CE analysis was performed on Agilent 3DCE G1600AX capillary 
electrophotography (Agilent, West Lothian, UK) controlled by 
Chemstation B.02.01 (Agilent, West Lothian, UK). The capillaries 
were from fused-silica (Agilent, West Lothian, UK) with a standard 
length of 48.5 cm and with an internal diameter 50 μm. The pres- 
sure injection mode was set for 4 s with 50 mbar at λ max = 210 nm 
and migration time equal to 6 min. The separation voltage was 
30 kV and the resulting current was approximately equal to 35 μA. 
Fused silica capillaries were ﬁ rstly conditioned by ﬂ ushing of 1 
M 
NaOH at > 950 mbar at 40 °C for 20 min followed by equilibration 
with running buﬀ er for 40 min applying the above-mentioned se- 
paration conditions. A buﬀ er system comprised from 50 mmol/l 
acetate,  850  mmol/l  2-(N-cyclohexylamino)  ethanesulfonic  acid 
 
(CHES) and 10% acetonitrile was used [10]. The virtual pH of the 
buﬀ er was adjusted to 7.8. 
 
 
2.6. Direct and indirect entrapment eﬃciency (EE) 
 
Insulin loading within NP matrix was determined directly by ex- 
traction from lyophilised NP or indirectly by analysing the supernatant 
(non-entrapped fraction during manufacturing process). The direct EE 
was calculated as a ratio of mass of the drug found in NP to mass of the 
drug initially added before NP fabrication. The extraction of insulin was 
applied by incubating an appropriate amount of NP with 1.0 M NaOH 
for 2–3 h at 37 °C followed by neutralisation with 1.0 M HCl [6]. This 
extract was analysed by bicinchoninic acid protein assay (BCA) kit to 
quantitate the amount of insulin directly entrapped in NP. Insulin 
concentration in the supernatant (indirect EE) was determined using 
RP-HPLC and CE, as described in section 2.5. The indirect EE (%) was 
calculated using the following Eq [11]. 
  
 
 
 
Fig. 2. Representative graphs showing zeta po- 
tential measurements of PLGA NP using Malvern 
DlS v.6.20 software. Reported graph showed 
good quality (red arrows) of nanoparticles pre- 
pared with (A) PLGA 2.5% w/w, (B) PLGA 7.5% 
w/w.  (For  interpretation  of  the  references  to 
colour in this ﬁ gure legend, the reader is referred 
to the web version of this article.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Indirect %EE 
Total mass of drug used (mg ) − mass of drug in supernatant (mg )   
TFA (80:20:0.1%) and added to the sample spot to enhance the ioni- 
sation of protein [12]. All measurements collected in linear positive 
= 
 
x 100 
Total mass of  drug used (mg) ionisation mode using 50 laser shots/spectrum and the accelerating 
voltage was maintained at 20,000 V. The nitrogen laser was set at 
337 nm and directed toward the concentrated area of the sample/ma- 
trix spot. The mass/charge  ratio (m/z) was plotted  against relative 
abundance. 
2.7. In vitro drug stability 
 
MALDI-TOF MS (Matrix assisted laser desorption ionisation time of 
ﬂ ight mass spectro-
metry). 
MALDI-TOF  MS  was  performed  using  a  PerSeptive  Biosystems 
Voyager-DE Biospectrometer (Hertfordshire, UK) equipped with a 1 m 
time-of- ﬂ ight tube. A 1.5   μL aliquot of insulin standard 
solution 
(30 μl ml−1) in 0.01 M HCl and insulin extracted from NP (obtained 
after dissolving 1 mg of insulin-NP by 200 μl DCM and addition of 
500 μl 0.01 M HCl to extract the entrapped insulin) were pipette onto a 
predeﬁ ned well of a 100-well stainless steel plate and allowed to dry 
at 
room  temperature.  A  1.5    μL  aliquot  of  CHCA  (α-cyano-4-hydro- 
xycinnamic acid) solution (10 mg/ml) was prepared in MeCN/H2O/ 
  
2.8. In vitro release 
kinetics 
 
The lyophilised insulin-loaded NP (15 mg) were dispersed in 1.0 ml 
phosphate-buﬀ ered saline solution (PBS, pH 7.4). The samples 
were 
incubated at 37 °C with agitation using a rotating mixer (Stuart 
Rotator Drive STR4, Bibby Scientiﬁ c Ltd., UK) at 100 rpm. The 
release medium 
was withdrawn at predetermined time intervals for 6 days after 
cen- trifugation at 5500 × g (Mini-Spin Eppendorf, Davidson & 
Hardy Ltd., UK) for 5 min. A fresh release media (1.0 ml) was 
replaced at each time interval [13]. The supernatant was analysed 
using RP-HPLC, as de- scribed previously in section 2.5. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. Eﬀ ect of PLGA concentration on insulin NP; (A) particle size and zeta 
potential, 
(B) entrapment eﬃciency measured indirectly by HPLC (Representative peak was shown 
in the upper left side of the graph). (Formulation codes shown in Table 1). Results show 
mean ± SD (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001 compared with 2.50% 
PLGA concentration. †P < 0.05, ††P < 0.01, †††P < 0.001 compared with 5.00% 
PLGA concentration. 
 
2.9. In vivo study 
 
This research protocol was approved by Ulster University's Animal 
Ethics  Committee  in  accordance  with  the  UK  Animals  (Scientiﬁ
c 
Procedures) Act of 1986. 
Fig. 4. Eﬀ ect of PVA concentration on insulin NP; (A) particle size and zeta potential, 
(B) entrapment eﬃciency measured indirectly by HPLC. Results show mean ± SD (n 
= 3). 
*P < 0.05, **P < 0.01, ***P < 0.001 compared with 1.25% PVA. †P < 0.05, 
††P < 0.01, †††P < 0.001 compared with 2.50% PVA. 
 
 
2.9.1. Induction of type I diabetes 
Diabetes was induced by intraperitoneal injection (I.P) of a single 
dose of streptozotocin (STZ) in 0.1 M sodium citrate buﬀ er (pH 4.5) at 
a 
dose of 50–60 mg kg−1 body weight [14]. The freshly prepared solution 
was injected immediately. Eighteen Male Sprague–Dawley rats (12- 
week-old) weighing 250–300 g were fasted for 6 h prior to injection. A 
blood  glucose  measurement  was  performed  48  h  after  STZ  injection 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
to be the same (25 IU kg−1). Glycaemia, in blood samples withdrawn 
from the tail vein, was measured before injection and 0.5, 3, 6, 12, 24, 
48, 72, 96, 120 and 144 h. Rats were maintained fasted for the ﬁ rst 12 
h 
of the experiment and fed thereafter [16]. 
 
2.10. Statistical analysis 
 
Data are presented as the mean ± standard deviation. Statistical 
analysis was performed using Prism 5 (Graph-Pad Software). A one-way 
ANOVA, followed by a pairwise comparison post-hoc test, was con- 
ducted wherever appropriate. The signiﬁ cance level for rejecting 
the 
null hypothesis was 5% (p < 0.05). Student's t-test was used to com- 
pare the hypoglycemic eﬀ ect of the subcutaneous administration 
of 
insulin PLGA NP, free insulin and insulin zinc suspension. 
 
3. Results and discussion 
 
In this study, several key processing parameters were investigated 
during fabrication of insulin- PLGA NP, as demonstrated in Table 1. 
Four independent factors, polymer concentration, the concentration 
and the molecular weight of PEG in the organic phase, PVA (surface 
modi ﬁ er) concentration in the external aqueous phase and the 
volume 
ratio of internal to external aqueous phases (IEPR) were examined to 
evaluate their inﬂ uences on the mean particle size, zeta potential, 
percentage EE, surface morphology and in-vitro release proﬁ le. 
The 
optimised  insulin  NP  formulation  was  selected  to  examine  its  hy- 
poglycaemic eﬀ ect comparing with free insulin and insulin-zinc 
sus- 
pension after subcutaneous injection in experimental rats. 
 
3.1. E ﬀ ect of process formulation 
variables 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5. Eﬀ ect of IEPR on insulin NP; (A) particle size and zeta potential, (B) 
entrapment eﬃciency measured indirectly by HPLC. Results show mean ± SD (n = 3). 
*P < 0.05, 
**P  < 0.01, ***P  < 0.001 compared with 0.010 IEPR. †P  < 0.05, ††P  < 0.01, 
†††P < 0.001compared with 0.015 IEPR. 
 
 
[15]. Blood was drawn from the tail vein and the glucose level de- 
termined using a glucometer (Lever Chek®, TalDoc Tech Corp, Ger- 
many). Rats with blood glucose levels > 250 mg dl−1 were considered 
to be in a diabetic state. 
 
2.9.2.  Experimental groups 
This study was conducted using three groups (n = 6) of diabetic rats 
(Male Sprague–Dawley) injected subcutaneously with: (i) free human 
insulin, (ii) insulin PLGA NP (F4), (iii) insulin zinc suspension. Free 
insulin and insulin NP were suspended in PBS and homogenously dis- 
persed before subcutaneous injection into the neck region at a dose of 
25 IU kg−1 body weight. The dose of insulin zinc suspension was kept 
  
3.1.1. PLGA 
concentration 
The mean particle size of formulations prepared using 2.5%, 
5.0%, or 7.5% (formulations M1 M10 and M19 as mentioned in 
Table 1) of PLGA resulted in 199.8 nm, 215.5 nm and 329.9 nm, 
respectively (Fig. 3A). The unimodal symmetric size distribution was 
seen in Fig. 1 with low polydispersity index values (PDI). 
Increasing the polymer concentration, while keeping the volume of 
organic phase constant at 
4 ml, the resistance of the organic phase to ﬂ ow is elevated, which 
leads 
to increase in the consistency of droplet and higher shear force to 
be broken, thus bigger oil droplets are formed with a signiﬁ
cantly in- 
creasing in particle size 
[17]. 
PLGA being a negative charged polymer imparts anionic nature 
to nanoparticles which depends on their molecular weight and con- 
centration as it is shown in Fig. 2 [18]. It was shown that increasing 
the 
polymer concentration from 2.5 to 5.0% of PLGA had no eﬀ ect on 
the 
surface charge (p > 0.05) (Fig. 3A), whereas increasing the 
polymer concentration to 7.5% led to signiﬁ cant increase in the 
negative value 
of zeta potential which might have a good impact on the stability of 
NP due to increase the electrostatic repulsion and more protection 
from aggregation [19]. Increasing PLGA concentration by 2.5% 
increments 
from 2.5% to 7.5% resulted in a signiﬁ cant increase in the percent 
of 
entrapment eﬃciency from 38.8% to 79.9% (Fig. 3B). The increase 
in 
polymer concentration increases the organic phase viscosity, 
which prevents the diﬀ usion of drug molecules out to aqueous 
phase during 
homogenisation step, thereby better drug entrapping within NP 
matrix 
[17
]. 
 
3.1.2. PVA 
concentration 
In this study, PVA, a water-soluble polymer with a high bio- 
compatibility and biodegradability [20] was selected and used as 
the surfactant added to the external aqueous phase during NP 
preparation to enhance their stability and redispersibility [21]. PVA 
(2.5% w/v) was 
also, added to the internal aqueous phase to promote the emulsiﬁ
cation 
of insulin solution in the organic phase (1ry  emulsion). The eﬀ ect 
of 
increasing PVA concentration varied from 1.25, 2.50 and 5.00% w/v 
on 
  
 
 
 
Table 2 
Physicochemical properties of insulin-PLGA NP formulations (F1-F7). Data represent mean values ± SD of at least three measurements. 
 
Formula Code Z-average 
(nm) 
Polydispersity index (PDI) Zeta potential (mV) % EE (Direct)a %EE (Indirect)b 
F1 297.82 ± 18.85 0.37 ± 0.06 −3.94 ± 0.02 56.94 ± 10.70 69.17 ± 0.60 
F2 459.07 ± 65.40 0.42 ± 0.26 −5.62 ± 0.28 – – 
F3 484.40 ± 75.53 0.49 ± 0 .04 −6.81 ± 0.13 – – 
F4 202.60 ± 20.60 0.38 ± 0.06 −5.71 ± 0.17 67.72 ± 5.42 69.50 ± 3.33 
F5 186.93 ± 14.03 0.26 ± 0.04 −5.75 ± 0.03 71.20 ± 7.68 69.60 ± 5.66 
F6 243.57 ± 16.51 0.35 ± 0.04 −7.52 ± 0.07 63.45 ± 8.28 73.74 ± 3.22 
F7 255.67 ± 28.94 0.38 ± 0.02 −8.76 ± 0.17 60.53 ± 9.83 69.73 ± 3.01 
a 
Direct EE is measured by BCA. 
b 
Indirect EE is measured by HPLC. Non-signiﬁ cant diﬀ erence between direct and indirect entrapment eﬃciency. 
 
Table 3 
Comparison between the percent entrapment eﬃciency (% EE) results of insulin- PLGA 
NP measured directly by BCA or indirectly by HPLC and CE. 
 
Formula Code Percent entrapment eﬃciency (% EE) measured by 
 
 BCA ***HPLC ***CE 
M1 20.10 ± 1.88 38.80 ± 3.53 55.85 ± 1.29 
M2 11.92 ± 0.71 27.65 ± 3.22 23.74 ± 4.37 
M3 03.81 ± 0.39 15.85 ± 3.17 21.04 ± 5.16 
M4 10.25 ± 0.80 36.92 ± 5.79 48.31 ± 7.54 
M5 05.94 ± 0.15 18.53 ± 4.73 17.84 ± 2.43 
M6 09.99 ± 0.11 15.86 ± 6.15 16.32 ± 1.41 
M7 10.97 ± 0.18 51.13 ± 4.40 55.06 ± 5.58 
M8 03.97 ± 0.50 25.30 ± 2.11 27.07 ± 3.17 
M9 02.39 ± 0.37 24.53 ± 2.43 30.84 ± 5.83 
M10 21.77 ± 3.35 46.55 ± 3.37 39.05 ± 4.50 
M11 06.46 ± 0.15 23.48 ± 3.51 17.57 ± 5.47 
M12 00.91 ± 0.05 16.81 ± 1.27 10.14 ± 2.45 
M13 21.19 ± 0.37 47.70 ± 5.10 36.52 ± 0.37 
M14 10.55 ± 0.45 27.41 ± 1.54 09.44 ± 4.63 
M15 06.12 ± 0.66 24.61 ± 0.22 07.75 ± 5.14 
M16 20.24 ± 2.15 48.71 ± 1.93 35.42 ± 3.21 
M17 16.86 ± 1.10 47.37 ± 4.27 30.11 ± 5.64 
M18 11.24 ± 0.14 40.33 ± 2.41 24.32 ± 4.34 
M19 49.99 ± 3.14 79.92 ± 2.04 76.99 ± 2.77 
M20 39.76 ± 3.09 57.35 ± 3.81 53.15 ± 3.07 
M21 30.12 ± 0.63 41.99 ± 3.95 35.91 ± 2.82 
M22 41.83 ± 1.97 64.72 ± 4.33 62.01 ± 1.63 
M23 22.76 ± 1.42 43.19 ± 1.18 39.33 ± 1.75 
M24 13.82 ± 0.89 31.63 ± 2.25 26.05 ± 0.84 
M25 39.28 ± 1.21 70.91 ± 2.38 73.39 ± 2.67 
M26 28.14 ± 0.82 58.13 ± 2.14 55.70 ± 2.98 
M27 21.03 ± 0.34 32.04 ± 2.81 28.54 ± 4.19 
***P < 0.001, a signiﬁ cant diﬀ erence between direct EE measured by BCA and 
indirect EE measured by HPLC and CE. Non-signiﬁ cant diﬀ erence between HPLC and 
CE results. 
 
 
the properties of insulin NP was seen in Fig. 4. Increasing PVA con- 
centration resulted in a signiﬁ cant increase in the mean particles size 
of 
NP at each polymer concentration used (Fig. 4A). Doelker et al. [22] 
and Quintanar-Guerrero et al. [23] reported that a decrease in size for 
increasing stabiliser concentration, PVA prevents oil droplets coales- 
cence and  maintains w1/o/w2 emulsion stability following NP pre- 
paration. Zweers et al. [21] mentioned that increasing PVA con- 
centration decreases NP size till an optimum concentration at maximum 
2.00% w/v and exceeding this level might aﬀ ect negatively on 
particle 
size. Hydrocarbon branches of PVA chains are possibly adsorbed on the 
surface of PLGA NP via hydrophobic bonding, and most of hydroxyl 
groups of PVA at high concentration (> 2% w/v) could be hydrated at 
the surface so, strong hydrogen bonds via hydroxyl groups will be 
formed between inter- or intra-molecules of PVA. This might produce 
aggregated NP leading to bigger particle size [24]. During NP pre- 
paration, pellets were collected and exposed to a washing process with 
three sequential steps using an optimum concentration of the cryo- 
protectant. PVA should be removed during this step leaving small re- 
sidual amount that might have non-signiﬁ cant eﬀ ect on the net surface 
  
 
Fig. 6. Scanning electron micrographs of naked free insulin before NP processing, 
(A) observed under low magniﬁ cation and (B) at higher magniﬁ cation. Bar in A 
represents 
5 μm and in B represents 1 
μm. 
 
 
charge of the lyophilised NP (Fig. 
4A). 
Increasing PVA concentration had variable e ﬀ ects on 
entrapment eﬃciency depending on the concentration of PLGA used 
(Fig. 4B). At 2.5% w/v of PLGA, increasing PVA concentration led 
to a signiﬁ cant increase in entrapment eﬃciency, this might be 
explained in terms of 
increased viscosity of the continuous phase with higher 
concentrations of PVA which resists drug diﬀ usion from the 
internal to the external 
aqueous phase resulting in higher drug loading [19], whereas, at 
5.00% w/v of PLGA, there is no signiﬁ cant eﬀ ect for increasing 
PVA con- centration. At 7.50% w/v of PLGA, entrapment eﬃ
ciency started to signi ﬁ cantly decrease with increasing PVA 
concentration. Insulin being 
a hydrophilic drug gets entrapped inside the PLGA nanoparticles 
(1ry emulsion) and PVA stabilizes the nanoparticles by diﬀ using 
out the 
water molecules forming the polymer rich coacervate [18]. At 
higher 
  
 
 
 
Fig. 7. Scanning electron micrographs of insulin-loaded NP. (M1: A & B), (M10: C & D), 
(F2: E & F) and (F4: G & H). A, C, E and G observed under low magniﬁ cation. B, D, F and 
H observed at higher magniﬁ cation. Images in I-K show polymeric structures of NP 
formula 
(F4) with voids following exposure to release phase media. Bars in I, J and K represent 
5 μm. 
 
 
concentration of PLGA (7.5%w/v), increasing concentration of PVA 
exhibited a higher aqueous solubility of drug by squeezing the nano- 
particles  which  in  turn  increased  the  partition  of  drug  out  to  the 
 
external aqueous phase and thereby resulted in decrease in entrapment 
of insulin inside the polymeric vesicle [25]. 
 
3.1.3. Internal to external phase volume ratio (IEPR) 
In order to study this factor, the volumes of the organic and external 
aqueous phases were held constant, whereas, the volume of internal 
aqueous phase in which the drug was dissolved varied from 0.50, 0.75 
and 1.00 ml. IEPR was calculated as a ratio between the volumes of 
internal to external (50 ml) aqueous phases. Fig. 5A showed the eﬀ
ect 
of IEPR on the zeta potential and particle size, increasing IEPR has no 
signiﬁ cant eﬀ ect on zeta potential. At PLGA concentrations of 2.50 
and 
5.00 %w/v, particle size increase with increasing IEPR. The lower vo- 
lume of internal aqueous phase resulted in a well-dispersed, eﬃcient 
homogenisation and stable w/o emulsion, which could probably reduce 
the frequency of collisions during the formation of NP in the second 
emulsiﬁ cation step, leading to a decrease in the particle size 
[26], 
higher volumes of internal aqueous phase led to bigger particle size. 
Increasing the viscosity of primary emulsion at high PLGA concentra- 
tion (7.5% w/v) led to decrease the particle size with increasing IEPR. 
Increasing the volume of internal aqueous phase might balance the 
resistance of viscous emulsion to shear stress produced from homo- 
genisation. NP size can be controlled, by the inner aqueous phase vo- 
lume via the inﬂ uence on emulsion viscosity 
[27]. 
It was found that IEPR has a signiﬁ cant eﬀ ect on the entrapment 
eﬃciency (Fig. 5B). Increasing IEPR resulted in decreasing % EE at each 
polymer concentration used. Higher volume of internal aqueous phase 
in proportional to a constant organic phase volume led to increase the 
tendency of the drug to migrate out the polymeric matrix to the ex- 
ternal aqueous phase that might decrease drug loading [28]. Li et al. 
mentioned in his work that, the protein entrapment eﬃciency is highly 
dependent on the thickness of the organic phase surrounding the aqu- 
eous solution of the drug to form the primary emulsion, increasing the 
volume of the internal aqueous phase might lead to weaken the tighten 
of organic phase and facilitate escaping of drug molecules to the ex- 
ternal aqueous phase [26]. 
 
3.1.4. PEG molecular weight and concentration 
PEG is a non-ionic polymer with good biocompatibility. The pre- 
sence of PEG rich layer as a periphery on NP reduces protein adsorption 
on the surface, which for PLGA-based NP will delay degradation and 
increase stability [29]. In this study, three diﬀ erent grades of 
PEG 
(200 Da, 2 and 5 kDa) with concentrations of 5.0 and 10.0 %w/w were 
used as shown in Table 1. PEG molecules are linked to NP via several 
methods that include covalent bonding, direct addition during NP 
preparation, or surface  adsorption. Here, the second approach was 
employed and PEG was mixed with PLGA in the organic phase during 
NP preparation. Table 2 showed the eﬀ ect of PEG content on 
NP 
characterisation in terms of particle size, PDI, zeta potential and en- 
trapment eﬃciency. Molecular weight of PEG has a signiﬁ cant eﬀ ect 
on 
the particle size. It was found that PEG with the lowest molecular 
weight (200 Da) has a negative impact on particle size leading to bigger 
diameter. PEG with the molecular weight of 2 kDa has more signiﬁ
cant 
eﬀ ect (p < 0.05) on particle size reduction than PEG with 
higher 
molecular weight (5 kDa). The addition of PEG modi ﬁ es the 
association 
of polymers during the formation of NP, which leads to a decrease in 
the resulting particle size, as observed in the literature of Beletsi et al., 
[30]. PEG with molecular weight higher than 1000 Da has better so- 
lubility in organic solvent such as DCM than PEG with molecular weight 
  
of 200–800 Da [31], which led to poor miscibility occurred 
between PEG (200 Da) and DCM during NP preparation and 
unexpected increase in the particle size of NP would exhibit. 
It was found that increasing PEG content (density and/or 
molecular weight) had no signiﬁ cant eﬀ ect on values of zeta 
potential. This might 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Fig. 8. MALDI-TOF mass spectrum of (A) an insulin standard 
and (B) insulin released from NP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
de due to physically addition of PEG to PLGA as we did not formulate 
PEG as a co-block with PLGA. As shown in Table 2, the direct and in- 
direct EE of F2 and F3 were not determined because of their big particle 
sizes   and   asymmetric   size   distribution   (high   PDI   values),   NP 
 
formulations (F2 and F3) were not used to complete further char- 
acterisation. The presence of PEG (2 and 5 kDa) resulted in a signiﬁ
cant increase in the direct EE with a greater eﬀ ect for PEG with 
molecular 
weight of 2 kDa (p < 0.05). PEG chains at the interface between the 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Fig. 9. In vitro drug release proﬁ les from insulin-loaded PLGA NP (Formulation 
codes shown in Table 1). For clarity, data are shown as mean + SD (n = 3). * 
Statistical 
signiﬁ cance (p < 0.05) between (F4-F7) and F1, ns (non-signiﬁ cant diﬀ erence) 
between 
FVII and FI. 
 
 
internal phase and the organic phase prevent drug molecules from 
migrating towards the external aqueous phase, which might result in 
the higher encapsulation eﬃciencies [32]. 
 
3.2. Direct and indirect entrapment eﬃciency 
 
The choice of method used to measure entrapment eﬃciency had a 
bearing on the estimate of entrapped drug. As demonstrated in Table 3, 
% EE measured directly by BCA was signiﬁ cantly (p < 0.05) less 
than 
%  EE  measured  indirectly  by  HPLC  or  CE,  whereas  non-signiﬁ
cant 
diﬀ erence was detected between indirect % EE values measured 
by 
 
HPLC and CE (p > 0.05). Higher values of % EE resulted in the in- 
direct EE methods comparing to direct EE method could be attributed 
that the indirect method for estimating EE (%) depends on detecting 
drug concentration in the supernatant and is, therefore, not a direct 
measure of particulate content. Indeed, further processing, such as 
washing and centrifugation, will remove loosely bound drug and so a 
preliminary analysis of the supernatant immediately following NP for- 
mation may be an overestimation. Although signiﬁ cantly diﬀ erent, 
the 
data in Table 2 does show reasonably good agreement between both 
methods for the NP formulations (F4-F7), so it can be concluded that 
the incorporated insulin is ﬁ rmly entrapped within the NP and 
not 
loosely bound to its surface. The EE of NP formulations (F2-F3) were 
not determined as mentioned in section 3.1.4. 
 
 
3.3. Morphological imaging 
 
Scanning electron microscopy was performed on naked free insulin 
and insulin NP to investigate the eﬀ ect of double emulsion solvent 
evaporation technique on the geometric shape and particle size. As it is 
shown in Fig. 6, free insulin has asymmetric irregular shape and bigger 
particle size with 4–5 μm range. Whereas, NP displayed a spherical 
geometry with smooth and pore-free surfaces (Fig. 7). The eﬀ ect 
of 
increasing PLGA concentration from 2.5% (Fig. 7 A & B)  to  5.0% 
(Fig. 7C & D) resulted in a signiﬁ cant increase in the particle size 
which 
showed a close matching with DLS results. 
The eﬀ ect of adding PEG is highly dependent on the molecular 
weight and concentration used. PEG with the lowest molecular weight 
(F2-F3) showed a signiﬁ cant bigger particle size and non-uniform 
size 
distribution (Fig. 7 E & F) as demonstrated in Table 2. We observed 
under scanning electron microscopy that PEG (200 Da) appeared as 
separate units with diﬀ erent shape containing several voids and 
bigger 
size (F2) which led to suboptimal in vitro characterisation of NP for- 
mulations (non-uniform geometrical shape, high PDI value and bigger 
particle size). 
The eﬀ ect of PEG (2 kDa), as represented by F4, decreased particle 
size and tightened the size distribution (Fig. 7 G & H) compared with 
M1 (Fig. 7 A & B). The residual appearance of NP following drug ex- 
traction after exposing to release medium for 48 h (Fig. 7I–K) showed 
large pores and voids with losing the spherical shape, which suggesting 
Fig. 10. Pro ﬁ les of glycaemia after a subcutaneous 
administra- tion  of  free  human  insulin  (triangles),  insulin-
loaded  nano- 
particles (circles) and insulin zinc suspension (squares) in dia- 
betic rats. Insulin was administered at the concentration of 25 
IU/kg. Before the injections, average blood glucose level was 
520.28 ± 58.60 mg/dL. Results are expressed as means ± SD. 
(n = 6 per group). Insulin NP was statistically diﬀ erent from 
free 
human insulin (**p < 0.01) and insulin zinc suspension 
(*p < 0.05). 
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a gradual erosion of polymer matrix to diﬀ use drug molecules out to 
the surrounding release medium. We found in this current work that 
the 
initial burst release in the ﬁ rst 12 h was likely attributed to diﬀ usion 
of 
the drug bound to the surface of polymer and the sustained release 
phase was due to gradual erosion of the polymer matrix which capsu- 
lated the drug molecules [33]. 
 
3.4. In vitro drug stability 
 
MALDI-TOF MS was used to compare the molecular weight of in- 
sulin standard (pure) to insulin extracted from NP. As it is shown in 
Fig. 8, the measured molecular weight of the standard (5793.40 Da) 
and the sample (5790.62 Da) are almost equal, conﬁ rming that 
the 
method  of  preparation  would  protect  the  drug  against  any  risk  of 
changing the architecture of insulin molecules following NP processing 
and storage. 
 
3.5. In vitro release proﬁ
le 
 
In vitro release experiment was performed for NP formulations 
(F1 & F4 - F7). Incorporation of PEG with optimum molecular weights 
and concentrations led to higher EE values with smaller particle sizes 
with 200–250 nm range. As it is shown in Fig. 9, an initial burst release 
was observed within the ﬁ rst 12 h followed by a sustained 
release 
proﬁ le over 144 h. Larger particles have a lesser initial burst and 
more 
sustained release than smaller particles. In addition, higher drug load- 
ings typically produce a higher initial burst and a faster release rate 
[29]. 
In vitro release proﬁ les for F4, F5 and F6 showed evidence of a 
burst release, with higher signiﬁ cant eﬀ ect for F4 and F5 than F6, 
which 
released approximately 65% and 34% of insulin, respectively, within 
the ﬁ rst 12 h, when compared to 19% of insulin released from 
F1 
(Fig. 9). Formulations containing PEG (F4-F6) had greater drug load- 
ings, which resulted  in  signiﬁ cant  higher  initial  burst  releases 
(p < 0.05). This initial burst release could be explained by the diﬀ
u- 
sion of drug molecules bound on the surface of the NP, which was 
enhanced by the addition of PEG [34]. PEG are hydrophilic chains, 
increases the porosity of the NP and improves water permeation to NP 
core which facilitates rapid insulin release in the ﬁ rst 12 h 
[35]. 
 
3.6. Subcutaneous delivery of insulin NP (In vivo study) 
 
A comparison between free insulin, insulin zinc suspension and in- 
sulin NP was performed in vivo using STZ induced diabetic rats. An 
optimised insulin NP (F4) was chosen based on their in vitro release 
pro ﬁ le which showed the highest initial burst peak with the 
maximum 
% cumulative release after 6 days, also, F4 has a high EE value with 
optimum particle size and low PDI. As shown in Fig. 10, the initial burst 
of insulin released from NP resulted in signiﬁ cantly hypoglycemic eﬀ
ect in the ﬁ rst 12 h to 14.76%, compared to 26.14% and 63.50% for 
insulin 
zinc suspension and free insulin respectively. Indeed, after the sub- 
cutaneous injection of free insulin (25 IU.kg−1), glycaemia decreased 
maximally by 16.59% after 30 min and started to increase after 3 h to 
34.48%. The continuous increase in the glycaemia level was maintained 
up to 12 h and zero time values were reached 24 h after the injection. 
Insulin  zinc  suspension  (25  IU.kg−1)  decrease  the  glycaemia  sig- 
niﬁ cantly (p < 0.001) to 36.57% after 30 min, the maximal 
decrease 
(18.90%) being reached after 6 h, the glucose level started to increase 
again restoring its initial value at 48 h post injection. Insulin NP pro- 
longed the hypoglycemic eﬀ ect with signiﬁ cantly decrease in the glu- 
cose level. Glucose level started to slightly increase at 48 h and till the 
end of experiment after 6 days, glucose level did not reach to its initial 
value and the hypoglycemia eﬀ ect was signiﬁ cantly lower (86.80%) 
than insulin zinc suspension (106.80%, p < 0.01) and free insulin 
(106.36%, p < 0.01). 
Thus, the hypoglycemic eﬀ ect of free insulin disappeared after 
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30 min, whereas encapsulated insulin and insulin zinc suspension 
re- mained active for more than 12 h after the injection. Insulin 
NP has 
signiﬁ cantly hypoglycemic eﬀ ect (p < 0.05) than insulin zinc 
sus- 
pension throughout the six days of the experiment. Nanoparticles en- 
capsulation technique maintains insulin activity for longer time 
[16]. Addition of PEG would increase the residence time of insulin 
in the blood circulation via scaping mononuclear phagocyte 
systems (MPS) 
[34] which oﬀ ers an advantage for insulin NP over insulin zinc 
sus- 
pension. 
 
4. Conclusion 
 
Double emulsion solvent evaporation technique is an optimum 
method used to prepare nanoparticles while maintaining stability 
and biological activity of protein or peptide during processing and 
release as 
conﬁ rmed by MALDI- TOF MS technique. Optimisation of the 
process 
variables during NP manufacturing is the crucial key to control in vitro 
characterisation of NP. Addition of PEG resulted in better 
entrapment eﬃ ciency, smaller particle size and sustained in vitro 
release proﬁ le for 6 days with initial burst at the ﬁ rst 12 h. A single 
weekly subcutaneous injection of optimised NP formulation is eﬃ
cient to sustain the delivery 
of insulin in streptozotocin induced diabetic rats. 
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